Even phII results aren't worth a lot when it comes to partnering unless they are really exceptional. The big pharma sector is a cut throat area. I hold Alchemia as well, with 3 Ph1, 3 Ph2 and 1 ph3 all but complete in pretty big money areas and we are still being priced at <$200m mc including an income stream of $10m pa from a generic we designed.
A completed ph3 is an entirely different matter as the product is de-risked. Ph1's have little value at all, but this one, with Professor Frazer's name attached should generate more interest than usual. I wouldn't like to see them partner on it though. Stunning results from a ph2 and I wouldn't mind as ph3 completion will be 3 years off I reckon.
Nice finish, page-54
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.00 |
Change
0.150(1.01%) |
Mkt cap ! $317.0M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.15 | $14.30 | $210.2K | 14.26K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $14.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.00 | 5153 | 3 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |